Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: A double-blind, placebo-controlled study

European Journal of Pain (United Kingdom)

Volumn 17, Issue 6, 2013, Pages 844-857

  Ostenfeld, Thor ^a   Krishen, A ^b   Lai, R Y ^a   Bullman, J ^a   Baines, A J ^a   Green, J ^a   Anand, P ^c   Kelly, M ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOSMAPIMOD; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NECK PAIN; NEUROPATHIC PAIN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL NERVE INJURY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; VITAL SIGN;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; CYCLOPROPANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURALGIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PAIN MEASUREMENT; PERIPHERAL NERVE INJURIES; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME;

EID: 84877086904     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1002/j.1532-2149.2012.00256.x     Document Type: Article

References (49)

1. Adams, J.L., Badger, A.M., Kumar, S., Lee, J.C. (2001). p38 MAP kinase: Molecular target for the inhibition of proinflammatory cytokines. Prog Med Chem 38, 1-60.
2. Alford, K.A., Glennie, S., Turrell, B.R., Rawlinson, L., Saklatvala, J., Dean, J.L. (2007). Heat shock protein 27 functions in inflammatory gene expression and transforming growth factor-beta-activated kinase-1 (TAK1)-mediated signaling. J Biol Chem 282, 6232-6241.
3. Anand, P., Shenoy, R., Palmer, J.E., Baines, A.J., Lai, R.Y., Robertson, J., Bird, N., Ostenfeld, T., Chizh, B.A. (2011). Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury. Eur J Pain 15, 1040-1048.
4. Cheriyan, J., Webb, A.J., Sarov-Blat, L., Elkhawad, M., Wallace, S.M., Maki-Petaja, K.M., Collier, D.J., Morgan, J., Fang, Z., Willette, R.N., Lepore, J.J., Cockcroft, J.R., Sprecher, D.L., Wilkinson, I.B. (2011). Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123, 515-523.
5. Coulthard, L.R., White, D.E., Jones, D.L., McDermott, M.F., Burchill, S.A. (2009). p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15, 369-379.
6. Dong, H., Tian, Y.K., Xiang, H.B., Tian, X.B., Jin, X.G. (2007). The cellular location and significance of p38alpha/beta isoforms in the lumbar spinal cord of the bone cancer pain rats. Zhonghua Yi Xue Za Zhi 87, 53-57.
7. Dworkin, R.H., Turk, D.C.,Wyrwich, K.W., Beaton, D., Cleeland, C.S., Farrar, J.T., Haythornthwaite, J.A., Jensen, M.P., Kerns, R.D., Ader, D.N., Brandenburg, N., Burke, L.B., Cella, D., Chandler, J., Cowan, P., Dimitrova, R., Dionne, R., Hertz, S., Jadad, A.R., Katz, N.P., Kehlet, H., Kramer, L.D., Manning, D.C., McCormick, C., McDermott, M.P., McQuay, H.J., Patel, S., Porter, L., Quessy, S., Rappaport, B.A., Rauschkolb, C., Revicki, D.A., Rothman, M., Schmader, K.E., Stacey, B.R., Stauffer, J.W., von Stein, T., White, R.E., Witter, J., Zavisic, S. (2008). Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9, 105-121.
8. Fitzsimmons, B.L., Zattoni, M., Svensson, C.I., Steinauer, J., Hua, X.Y., Yaksh, T.L. (2010). Role of spinal p38alpha and beta MAPK in inflammatory hyperalgesia and spinal COX-2 expression. Neuroreport 21, 313-317.
9. Galer, B.S., Jensen, M.P. (1997). Development and preliminary validation of a pain measure specific to neuropathic pain: The Neuropathic Pain Scale. Neurology 48, 332-338.
10. Genovese, M.C. (2009). Inhibition of p38: Has the fat lady sung? Arthritis Rheum 60, 317-320.
11. Gordh, T.E., Stubhaug, A., Jensen, T.S., Arner, S., Biber, B., Boivie, J., Mannheimer, C., Kalliomaki, J., Kalso, E. (2008). Gabapentin in traumatic nerve injury pain: A randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 138, 255-266.
12. Hua, X.Y., Svensson, C.I., Matsui, T., Fitzsimmons, B., Yaksh, T.L., Webb, M. (2005). Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia. Eur J Neurosci 22, 2431-2440.
13. Hudmon, A., Choi, J.S., Tyrrell, L., Black, J.A., Rush, A.M., Waxman, S.G., Dib-Hajj, S.D. (2008). Phosphorylation of sodium channel Nav1.8 by p38 mitogen-activated protein kinase increases current density in dorsal root ganglion neurons. J Neurosci 28, 3190-3201.
14. Ji, R.R. (2004). Peripheral and central mechanisms of inflammatory pain, with emphasis on MAP kinases. Curr Drug Targets Inflamm Allergy 3, 299-303.
15. Ji, R.R., Samad, T.A., Jin, S.X., Schmoll, R., Woolf, C.J. (2002). p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36, 57-68.
16. Ji, R.R., Suter, M.R. (2007). p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 3, 33.
17. Ji, R.R., Woolf, C.J. (2001). Neuronal plasticity and signal transduction in nociceptive neurons: Implications for the initiation and maintenance of pathological pain. Neurobiol Dis 8, 1-10.
18. Jin, S.X., Zhuang, Z.Y.,Woolf, C.J., Ji, R.R. (2003). p38 mitogenactivated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23, 4017-4022.
19. Kumar, S., Boehm, J., Lee, J.C. (2003). p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2, 717-726.
20. Lim, E.J., Jeon, H.J., Yang, G.Y., Lee, M.K., Ju, J.S., Han, S.R., Ahn, D.K. (2007). Intracisternal administration of mitogenactivated protein kinase inhibitors reduced mechanical allodynia following chronic constriction injury of infraorbital nerve in rats. Prog Neuropsychopharmacol Biol Psychiatry 31, 1322-1329.
21. Liu, S., Yang, J., Wang, L., Jiang, M., Qiu, Q., Ma, Z., Liu, L., Li, C., Ren, C., Zhou, J., Li, W. (2010). Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res 1346, 213-223.
22. Lomas, D.A., Lipson, D.A., Miller, B.E., Willits, L., Keene, O., Barnacle, H., Barnes, N.C., Tal-Singer, R. (2012). An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 52, 416-424.
23. McNair, D.M., Lorr, M., Droppleman, L.F. (1981). Profile of Mood States (POMS) Manual (San Diego, CA: Educational and Industrial Testing Service).
24. Melzack, R. (1987). The short-form McGill Pain Questionnaire. Pain 30, 191-197.
25. Milligan, E.D., Twining, C., Chacur, M., Biedenkapp, J., O'Connor, K., Poole, S., Tracey, K., Martin, D., Maier, S.F., Watkins, L.R. (2003). Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 23, 1026-1040.
26. Obata, K., Katsura, H., Mizushima, T., Yamanaka, H., Kobayashi, K., Dai, Y., Fukuoka, T., Tokunaga, A., Tominaga, M., Noguchi, K. (2005). TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest 115, 2393-2401.
27. Obata, K., Yamanaka, H., Dai, Y., Mizushima, T., Fukuoka, T., Tokunaga, A., Noguchi, K. (2004). Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur J Neurosci 20, 2881-2895.
28. Pargellis, C., Regan, J. (2003). Inhibitors of p38 mitogenactivated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Investig Drugs 4, 566-571.
29. Pocock, J.M., Liddle, A.C. (2001). Microglial signalling cascades in neurodegenerative disease. Prog Brain Res 132, 555-565.
30. Rosenstock, J., Tuchman, M., LaMoreaux, L., Sharma, U. (2004). Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 110, 628-638.
31. Sabatowski, R., Galvez, R., Cherry, D.A., Jacquot, F., Vincent, E., Maisonobe, P., Versavel, M. (2004). Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebocontrolled clinical trial. Pain 109, 26-35.
32. Schieven, G.L. (2009). The p38alpha kinase plays a central role in inflammation. Curr Top Med Chem 9, 1038-1048.
33. Schindler, J.F., Monahan, J.B., Smith,W.G. (2007). p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 86, 800-811.
34. Schreiber, S., Feagan, B., D'Haens, G., Colombel, J.F., Geboes, K., Yurcov, M., Isakov, V., Golovenko, O., Bernstein, C.N., Ludwig, D.,Winter, T., Meier, U., Yong, C., Steffgen, J. (2006). Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: A randomized, doubleblind, placebo-controlled trial. Clin Gastroenterol Hepatol 4, 325-334.
35. Selness, S.R., Devraj, R.V., Devadas, B., Walker, J.K., Boehm, T.L., Durley, R.C., Shieh, H., Xing, L., Rucker, P.V., Jerome, K.D., Benson, A.G., Marrufo, L.D., Madsen, H.M., Hitchcock, J., Owen, T.J., Christie, L., Promo, M.A., Hickory, B.S., Alvira, E., Naing, W., Blevis-Bal, R., Messing, D., Yang, J., Mao, M.K., Yalamanchili, G., Vonder, E.R., Hirsch, J., Saabye, M., Bonar, S., Webb, E., Anderson, G., Monahan, J.B. (2011). Discovery of PH-797804, a highly selective and potent inhibitor of p38 MAP kinase. Bioorg Med Chem Lett 21, 4066-4071.
36. Svensson, C.I., Fitzsimmons, B., Azizi, S., Powell, H.C., Hua, X.Y., Yaksh, T.L. (2005). Spinal p38beta isoform mediates tissue injury-induced hyperalgesia and spinal sensitization. J Neurochem 92, 1508-1520.
37. Svensson, C.I., Marsala, M., Westerlund, A., Calcutt, N.A., Campana, W.M., Freshwater, J.D., Catalano, R., Feng, Y., Protter, A.A., Scott, B., Yaksh, T.L. (2003). Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 86, 1534-1544.
38. Svensson, C.I., Medicherla, S., Malkmus, S., Jiang, Y., Ma, J.Y., Kerr, I., Brainin-Mattos, J., Powell, H.C., Luo, Z.D., Chakravarty, S., Dugar, S., Higgins, L.S., Protter, A.A., Yaksh, T.L. (2008). Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain. Pharmacol Biochem Behav 90, 664-675.
39. Sweitzer, S.M., Medicherla, S., Almirez, R., Dugar, S., Chakravarty, S., Shumilla, J.A., Yeomans, D.C., Protter, A.A. (2004). Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 109, 409-419.
40. Tong, S.E., Daniles, S.E., Montano, T., Chang, S., Desjardins, P. (2004). SCIO-469, a novel P38A MAPK inhibitor, provides efficacy in acute post-surgical dental pain. Clin Pharmacol Ther 75, P3.
41. Tsuda, M., Inoue, K., Salter, M.W. (2005). Neuropathic pain and spinal microglia: A big problem from molecules in 'small' glia. Trends Neurosci 28, 101-107.
42. Tsuda, M., Mizokoshi, A., Shigemoto-Mogami, Y., Koizumi, S., Inoue, K. (2004). Activation of p38 mitogen-activated protein kinase in spinal hyperactive microglia contributes to pain hypersensitivity following peripheral nerve injury. Glia 45, 89-95.
43. van Seventer, R., Bach, F.W., Toth, C.C., Serpell, M., Temple, J., Murphy, T.K., Nimour, M. (2010). Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: A randomized double-blind trial. Eur J Neurol 17, 1082-1089.
44. van Seventer, R., Feister, H.A., Young, J.P., Jr, Stoker, M., Versavel, M., Rigaudy, L. (2006). Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: A 13-week, randomized trial. Curr Med Res Opin 22, 375-384.
45. Ware, J.E., Jr, Sherbourne, C.D. (1992). The MOS 36-item shortform health survey (SF-36). I. Conceptual framework and item selection. Med Care 30, 473-483.
46. Wen, Y.R., Suter, M.R., Kawasaki, Y., Huang, J., Pertin, M., Kohno, T., Berde, C.B., Decosterd, I., Ji, R.R. (2007). Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model. Anesthesiology 107, 312-321.
47. Widmann, C., Gibson, S., Jarpe, M.B., Johnson, G.L. (1999). Mitogen-activated protein kinase: Conservation of a threekinase module from yeast to human. Physiol Rev 79, 143-180.
48. Xu, J.T., Xin, W.J., Wei, X.H., Wu, C.Y., Ge, Y.X., Liu, Y.L., Zang, Y., Zhang, T., Li, Y.Y., Liu, X.G. (2007a). p38 activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury. Exp Neurol 204, 355-365.
49. Xu, L., Huang, Y., Yu, X., Yue, J., Yang, N., Zuo, P. (2007b). The influence of p38 mitogen-activated protein kinase inhibitor on synthesis of inflammatory cytokine tumor necrosis factor alpha in spinal cord of rats with chronic constriction injury. Anesth Analg 105, 1838-1844.